Generic Name: relugolix

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Myovant Sciences

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Orgovyx is a GnRH agonist approved for the treatment of people with advanced prostate cancer. It is the first oral medication in its class.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Gonadotropin-releasing hormone (GnRH) agonists, also known as luteinizing hormone-releasing hormone (LHRH) agonists, block signals in the brain that direct the testicles to produce testosterone.

The Phase III HERO study showed that Orgovyx lowered testosterone levels at least as much as the long-acting injectable GnRH agonist Lupron (leuprolide) in men with advanced prostate cancer, and it did so more rapidly in a matter of days. Men who took Orgovyx had fewer serious cardiovascular events than those who used Lupron. Orgovyx was first approved in December 2020.


Dosing Info:

Orgovyx is taken as a tablet once daily.

Side Effects

Common side effects include hot flashes, muscle and bone pain, fatigue, constipation and diarrhea. Laboratory abnormalities include elevated glucose and triglycerides, decreased hemoglobin (anemia), and elevated ALT and AST liver enzymes. Potential serious side effects include heart rhythm abnormalities. Medications that lower testosterone may lead to reduced sexual desire, erectile dysfunction and shrinkage of the testicles. Orgovyx can cause fetal harm if exposure occurs during pregnancy.

For More Info:

Last Reviewed: December 20, 2020